Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Dufour

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Gut|July 16, 2008
Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infectionB Helbling, K Overbeck, J-J Gonvers, et al.
Journal of Hepatology|March 11, 2014
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinomaY-L Liu, G L Patman, J B S Leathart, et al.
Oncogene|March 18, 2014
Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motilityV Edmond, F Dufour, G Poiroux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)D Koeberle, J-F Dufour, G Demeter, et al.
Journal of Viral Hepatitis|November 18, 2015
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirinG R Foster, P Ferenci, T Asselah, et al.
Journal of Viral Hepatitis|October 15, 2013
The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infectionA J van der Meer, B J Veldt, J J Feld, et al.
Alimentary Pharmacology & Therapeutics|August 24, 2016
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological referenceM Munteanu, D Tiniakos, Q Anstee, et al.
The Pharmacogenomics Journal|December 9, 2015
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantationL Quteineh, P-Y Bochud, D Golshayan, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 1996
Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia geneR B Amson, M Nemani, J P Roperch, et al.
Gut|September 13, 2014
Impact of common risk factors of fibrosis progression in chronic hepatitis CS Rüeger, P-Y Bochud, J-F Dufour, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Gut|July 16, 2008
Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infectionB Helbling, K Overbeck, J-J Gonvers, et al.
Journal of Hepatology|March 11, 2014
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinomaY-L Liu, G L Patman, J B S Leathart, et al.
Oncogene|March 18, 2014
Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motilityV Edmond, F Dufour, G Poiroux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2016
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)D Koeberle, J-F Dufour, G Demeter, et al.
Journal of Viral Hepatitis|November 18, 2015
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirinG R Foster, P Ferenci, T Asselah, et al.
Journal of Viral Hepatitis|October 15, 2013
The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infectionA J van der Meer, B J Veldt, J J Feld, et al.
Alimentary Pharmacology & Therapeutics|August 24, 2016
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological referenceM Munteanu, D Tiniakos, Q Anstee, et al.
The Pharmacogenomics Journal|December 9, 2015
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantationL Quteineh, P-Y Bochud, D Golshayan, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 1996
Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia geneR B Amson, M Nemani, J P Roperch, et al.
Gut|September 13, 2014
Impact of common risk factors of fibrosis progression in chronic hepatitis CS Rüeger, P-Y Bochud, J-F Dufour, et al.
Pageof 12